-
Prof. Makoto Aihara, M.D. Ph.D. a former president of the society, is a clinician specializing in glaucoma. His clinical interests are medical and surgical treatment, with a particular focus on IOP regulation, inhibition of scarring following surgery, pathogenesis of glaucoma subtypes, and development and analysis of glaucoma animal models. As a member of the International Relations Committee, Budget and Management Committee, and Glaucoma Trend Survey Committee, he will endeavor to promote the interests of the society.
-
Prof. Masaru Inatani MD. PhD. is the Chairman of the Academic Committee. The committee supports glaucoma research through funding, promoting basic research in glaucoma, and facilitating international collaborative research. The aim is to develop new treatments for glaucoma, ultimately improving the quality of life for patients. As part of the JGS's research project promotion initiative, Prof. Inatani is responsible for glaucoma implant research. He will continue to support initiatives that enable researchers to express their creativity and pursue innovative ideas.
-
Prof. Toshihiro Inoue, MD, PhD, has been appointed as the chairperson of the Communications Committee. He is mainly in charge of the website. In addition to the information that has been accumulated so far, new projects will be reflected on the website, and new initiatives such as newsletters will be published in collaboration with the President, Awareness Promotion Committee, and Academic Committee to provide everyone with accurate, useful, and up-to-date information.
-
Prof. Kenji Kashiwagi MD. PhD. at the Department of Ophthalmology, University of Yamanashi, is currently active in the Big Data, AI Application Committee and the Glaucoma Gene Research Group of the JGS. He believes that in glaucoma treatment, which requires lifelong management, it is crucial to provide appropriate medical care and improve glaucoma care as a whole by integrating real-world data collected through glaucoma care and translational research. He would like to work to reduce the number of patients whose quality of life has been reduced by glaucoma.
-
Dr. Yasuo Kurimoto, MD, PhD. is the Director of Kobe City Eye Hospital. As a board member of the JGS, he serves as the Chairman of the Budget and Management Committee and a member of the International Relations Committee (in charge of APAO). He has been involved in glaucoma treatment and clinical research for many years, specializing in the pathogenesis and treatment of primary angle closure disease, essentially 'curable glaucoma’. He is also involved in the development of iPS cell-based retinal regeneration therapies, currently targeting the outer retina, and hopes to eventually advance his clinical research to the treatment of retinal ganglion cell impairment, the true cause of glaucoma.
-
As a member of the Awareness Promotion Committee, Prof. Masaki Tanito MD. PhD. chairs the Light-Up in Green Japan Executive Committee. The campaign started in 2015 in five locations. Today, the movement has expanded and has become a large-scale movement with the participation of over 1,500 public facilities, medical institutions, and others. At the JGS he wants to deliver the message of 'early detection, continuity and hope' to as many people as possible in order to reduce visual impairment caused by glaucoma.
-
Prof. Toru Nakazawa MD. PhD. is engaged in public relations activities and genetic research. In order to prevent blindness from glaucoma, it is required to promote research on pathological elucidation, which leads to new drugs discovery, by collecting data related to genetic background, medical care and lifestyle. The JGS has organized “The Research project of glaucoma omics” to conduct multi-institutional genetic research. The research group has discovered genetic disorders unique to the Japanese and their gene mechanism. The findings of this research need to be disseminated among young doctors in Japan and abroad.
-
Professor Tadashi Nakano MD. PhD. is Chair of the Awareness Promotion Committee, assigned to raising awareness about glaucoma, a disease with few noticeable symptoms. Many people live unaware that they have been affected. The committee promotes the importance of early diagnosis and strengthening collaboration with patients, healthcare providers, and local communities. He aims to create an environment where individuals diagnosed with glaucoma can quickly access appropriate treatment.
-
Prof. Makoto Nakamura, MD. PhD., Professor and Chairman of Kobe University Graduate School of Medicine, has been conducting translational and clinical research with the goal of elucidating the pathogenesis of glaucomatous optic neuropathy and finding treatments for the disease. His current research focuses on basic and clinical studies of the neuroprotective effects of metformin. As a member of the Board of Directors of the JGS, he chairs the Registry Promotion Committee and is a member of the Academic Committee. He is assembling the necessary evidence needed for the revision of the glaucoma practice guidelines.
-
Prof. Tomomi Higashide, M.D., Ph.D., from the Department of Ophthalmology, Kanazawa University Graduate School of Medical Sciences, has been appointed to the Board of Directors of the Japanese Glaucoma Society. He will be in charge of editing the society's journal "Glaucoma" and promoting projects such as Preperimetric Glaucoma and Glaucoma Suspect Study (PreGlass).
-
Prof. Takeo Fukuchi MD. PhD. continues to serve as chairperson of the Glaucoma Trend Survey Committee. During Professor Aihara's two four-year terms as president, he conducted a total of three questionnaire surveys on treatment and management status covering six themes about glaucoma. JGS has outlined the current standard glaucoma treatment in Japan through its treatment guidelines. This survey was a good opportunity to understand how these are being addressed in clinical practice. This will be his last term as a director of JGS. He wishes to continue to be active in his support of the society both in the clinical field in in the activities of the society.
-
Dr. Megumi Honjo, MD, PhD. is the associate professor in the department of ophthalmology at Tokyo University, Japan. She is a clinician scientist in glaucoma. Her research interests include development of glaucoma medicine for IOP regulation and inhibition of scarring following surgery, glaucoma pathophysiology, and glaucoma surgery. As a member of the board of directors of the JGS, she serves as the chairman of the Social Insurance Committee, and a member of International Relations Committee. Her goal as a member of the JGS is to provide better glaucoma treatment to patients, and promote glaucoma research in Japan while deepening international collaboration.
-
Prof. Atsuya Miki, MD, PhD. is the professor of ophthalmology and myopia control research at Aichi Medical University, Aichi, Japan. He is a clinician, surgeon, and a scientist specializing in glaucoma. His research interests include ocular imaging, ocular biomechanics, and glaucoma surgery. As a member of the board of directors of JGS, he serves as the vice chair of Social Insurance Committee, and Big Data, AI Application Committee, and a member of International Relations Committee. His goal as a member of the JGS is to enhance international collaboration and facilitate communication among glaucoma specialists in Japan, particularly among young ophthalmologists.
-
Dr. Kazuhiko Mori, M.D., Ph.D. is the director of Baptist Eye Institute, Nagaoka-kyo division and a visiting professor of ophthalmology at Kyoto Prefectural University of Medicine, Kyoto, Japan. He is a clinician scientist in glaucoma, known as the inventor of Mori upright surgical gonio lens. His special interests are glaucoma surgery, genetics, and trabecular outflow facilities. As a member of the Board of Directors of JGS, he serves as APGS Director, member of the Big Data, AI Application Committee and a member of the International Relations Committee. Through these activities, he intends to increase the international presence of JGS, particularly in the Asia-Pacific region, and to make every possible effort to provide better, state-of-the-art medical care to Japanese glaucoma patients.
